Review Article

Hyperostosis Frontalis Interna

Volume 26 · Issue 4 Publish Date: December 1, 2022
Full Text PDF
DOI
Ömercan Topaloğlu
Department of Endocrinology and Metabolism, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
Taner Bayraktaroğlu
Department of Endocrinology and Metabolism, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
Sakin Tekin
Department of Endocrinology and Metabolism, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
Seda Nur Topaloğlu
Department of Internal Medicine, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
İbrahim Şahin
Department of Endocrinology and Metabolism, İnönü University Faculty of Medicine, Malatya, Turkey
Zeynep Cantürk
Kocaeli University, Medical Faculty, Endocrinology and Metabolism, Kocaeli, Turkey
Topaloğlu, Ömercan, Bayraktaroğlu, T., Tekin, S., Topaloğlu, S. N., Şahin, İbrahim, & Cantürk, Z. (2022). Hyperostosis Frontalis Interna. Endocrinology Research and Practice, 26(4), 213–216. https://doi.org/10.5152/tjem.2022.22037
Full Text Full Text PDF

Abstract

Hyperostosis frontalis interna is the thickening of the inner layer of the frontal bone due to the formation of cancellous bone. In hyperostosis frontalis interna, nodular protrusions occur due to the formation of cancellous bone in the inner table of frontal bone. These nodular protrusions may be unilateral or on both sides of the midline but spare midline. Hyperostosis frontalis interna is associated with aging, obesity, menopause, or other endocrinopathies such as diabetes mellitus. The prevalence is shown to be 5%-12% in autopsy series or imaging-based studies. It may be classified according to the extensiveness and appearance of the lesion. The clinical significance is not clear, and hyperostosis frontalis interna is generally an incidental finding detected by imaging methods. But, sometimes headache, dural irritation, or brain atrophy may occur. Neurological or mental signs may be associated with hyperostosis frontalis interna. Underlying endocrinopathies (acromegaly, primary hyperparathyroidism, osteopetrosis, fibrous dysplasia, or Paget's disease) or malignancies should be excluded. Treatment is supportive and needs to be planned against the underlying disease.

Cite this article as: Topaloğlu Ö, Bayraktaroğlu T, Tekin S, Topaloğlu SN, Şahin İ, Cantürk Z. Hyperostosis frontalis interna. Turk J Endocrinol Metab. 2022;26(4):213-216.

Article Info
Published In
Journal Endocrinology Research and Practice
Volume / Issue Volume 26 · Issue 4
Pages 213-216
History
Published Online December 1, 2022
Copyright
Affiliations
Ömercan Topaloğlu
Department of Endocrinology and Metabolism, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
Taner Bayraktaroğlu
Department of Endocrinology and Metabolism, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
Sakin Tekin
Department of Endocrinology and Metabolism, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
Seda Nur Topaloğlu
Department of Internal Medicine, Zonguldak Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey
İbrahim Şahin
Department of Endocrinology and Metabolism, İnönü University Faculty of Medicine, Malatya, Turkey
Zeynep Cantürk
Kocaeli University, Medical Faculty, Endocrinology and Metabolism, Kocaeli, Turkey
Cite this Article
Topaloğlu, Ömercan, Bayraktaroğlu, T., Tekin, S., Topaloğlu, S. N., Şahin, İbrahim, & Cantürk, Z. (2022). Hyperostosis Frontalis Interna. Endocrinology Research and Practice, 26(4), 213–216. https://doi.org/10.5152/tjem.2022.22037
Outlines